本帖最后由 老马 于 2012-1-13 21:20 编辑 8 h: D4 z- E& H# ^6 ~' _# ]& Y5 m
4 B9 p: m7 g) V
爱必妥和阿瓦斯丁的比较 G2 ~5 Q, U( n) i) p, `
' C; J! g& M4 ?: phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 E4 g |# A* U$ }4 m; k
8 [: ?/ }9 H% b" G$ g9 ?
! O5 B9 R% V+ H* r0 x ehttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 M* N/ J: Q2 t2 F. ^2 n* m==================================================, [9 A7 C9 ]1 L+ }" V% j& p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: o; G! t, G, h+ mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, [- W1 n$ ~2 h7 m1 h- ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.( A" i/ E4 L5 b: F; o& O& J% s
|